Can a basal cell carcinoma convert into squamous cell carcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can a Basal Cell Carcinoma Transform into Squamous Cell Carcinoma?

Yes, a basal cell carcinoma can undergo partial squamous metaplasia and develop squamous cell carcinoma features, creating what is known as a basosquamous carcinoma—a truly biphenotypic tumor that should be treated as squamous cell carcinoma due to its higher metastatic potential. 1

Understanding Basosquamous Carcinoma

The National Comprehensive Cancer Network recognizes two distinct mechanisms by which a lesion can contain both basal and squamous cell features: 1

Two Pathways of Development

  • Collision tumors: Some basosquamous carcinomas result from a basal cell cancer physically colliding with an adjacent squamous cell cancer 1

  • True transformation: Others represent genuinely biphenotypic tumors, many of which may have started as basal cell cancer but subsequently underwent prominent partial squamous metaplasia 1

Histologic Characteristics

  • These tumors display one area with histologic appearance of basal cell carcinoma and another area with squamous cell carcinoma features 1

  • A transition zone typically links the two components 2

  • The squamous component determines the tumor's metastatic risk 1

Critical Clinical Implications

Treatment Approach

Basosquamous carcinomas must be conceptualized and treated as squamous cell cancers, not basal cell cancers, because their metastatic capacity resembles squamous cell carcinoma rather than basal cell carcinoma. 1

Why This Matters for Morbidity and Mortality

  • Basal cell carcinomas rarely metastasize and have excellent prognosis 3, 4

  • Squamous cell carcinomas have significantly higher metastatic potential 1

  • The squamous component in basosquamous tumors confers the higher-risk behavior pattern 1

  • Several studies demonstrate that basosquamous carcinomas have metastatic capacity more similar to squamous cell cancer than basal cell cancer 1

Risk Stratification

When a basosquamous carcinoma is identified, assess for high-risk features that increase recurrence and metastasis risk: 1, 5

  • Perineural involvement (significantly increases risk) 1, 5
  • Poor differentiation 1, 5
  • Desmoplastic features 1, 5
  • Deep invasion into reticular dermis or subcutaneous fat 1, 5
  • Rapidly growing tumor 1
  • Location at site of chronic inflammation or scarring 1

Common Pitfalls to Avoid

  • Do not treat basosquamous carcinoma as a low-risk basal cell carcinoma—this underestimates metastatic potential and may lead to inadequate treatment 1

  • Ensure adequate biopsy sampling—superficial biopsies may miss the squamous component, leading to misclassification 2, 6

  • Do not rely solely on clinical appearance—dermoscopic features show BCC-dominant vasculature with SCC-dominant morphology, making clinical diagnosis challenging 6

Diagnostic Confirmation

  • Histopathological examination is essential for definitive diagnosis 7, 8

  • Immunohistochemistry can help differentiate components: Ber-EP4 is positive in BCC areas with diminished staining in transition zones 2

  • The biopsy should sample the most abnormal-appearing area to capture both components 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Superficially Invasive Squamous Cell Carcinoma: Aggressiveness Assessment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Basosquamous carcinoma: Dermoscopic clues to diagnosis.

The Journal of dermatology, 2017

Guideline

Atrophic Patterns Affecting Basal Cells in Dermatological Disorders

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the best course of action for a 65-year-old male patient with a history of basal cell carcinoma (BCC) and a non-healing lesion in the cervical area, pending biopsy results?
What is the most likely diagnosis for a patient with a 1.5 cm erythematous nodule on the cheek with central ulceration and crust, accompanied by intermittent itching and bleeding?
What are the characteristics and treatment options for suspicious skin lesions, such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), with unusual appearance?
What is the differential diagnosis for an elderly female with a history of sun exposure presenting with a flesh-colored raised lesion on the eyebrow?
What are the primary types of skin malignancy?
What is the recommended acute‑attack treatment and long‑term urate‑lowering strategy for an adult with gout without severe renal impairment, cardiovascular disease, or peptic ulcer disease?
What ICD‑10‑CM code should be used for a screening check of serum magnesium?
In a patient with mild obstructive sleep apnea who wants a medication to improve daytime alertness, what is the safest treatment approach?
What is the recommended weekly dosing frequency of ketamine for treatment‑resistant depression and chronic pain?
What do I need to know about starting isotretinoin (Accutane) for a patient with severe refractory nodular/cystic acne, including contraindications, baseline laboratory tests, dosing regimen, monitoring, pregnancy‑prevention requirements, and potential adverse effects?
What is the best first‑line selective serotonin reuptake inhibitor for anxiety in a 17‑year‑old female with ADHD treated with 36 mg methylphenidate, and asthma managed with montelukast, cetirizine, beclomethasone inhaler, fluticasone nasal spray, albuterol, and dupilumab?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.